By Heather Slowik
2003 marks an anniversary of sorts for the pharmaceutical industry: call it Managed Care Mania. A decade ago, bracing for...
WellPoint: Revitalizing Managed Care
WellPoint is on a mission to manage spiraling drug costs. Perhaps best known for its role in pushing Claritin over-the-counter, its OTC strategy provides real cost savings and also reveals the company's aggressive mindset for dealing with its critical cost drivers. Fresh from its Claritin OTC victory, WellPoint launched its latest expense-reduction program, GenericSelect, to promote generic substitution for all prescription drugs within certain therapeutic categories. And in a separate effort, WellPoint is exploring therapeutic substitution, the switch of one branded drug for another, when there is not a generic option in a class of drugs. If WellPoint demonstrates continued success with its strategies, managed care in general may begin to undertake the type of aggressive formulary management that was promised back in the early 1990s.
More from Leadership
More from In Vivo
• By
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
• By
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
• By
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.